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Abstract
Background: In recent years there has been an exponential increase in tungsten demand, potentially increasing human
exposure to the metal. Currently, the toxicology of tungsten is poorly understood, but mounting evidence suggests that
both the elemental metal and its alloys have cytotoxic effects. Here, we investigate the association between tungsten and
cardiovascular disease (CVD) or stroke using six waves of the National Health and Nutrition Examination Survey (NHANES).
Methods: We investigated associations using crude and adjusted logistic regression models in a cohort of 8614 adults (18–
74 years) with 193 reported stroke diagnoses and 428 reported diagnoses of CVD. We also stratified our data to characterize
associations in a subset of younger individuals (18–50 years).
Results: Elevated tungsten concentrations were strongly associated with an increase in the prevalence of stroke,
independent of typical risk factors (Odds Ratio (OR): 1.66, 95% Confidence Interval (95% CI): 1.17, 2.34). The association
between tungsten and stroke in the young age category was still evident (OR: 2.17, 95% CI: 1.33, 3.53).
Conclusion: This study represents the most comprehensive analysis of the human health effects of tungsten to date.
Individuals with higher urinary tungsten concentrations have double the odds of reported stroke. We hypothesize that the
pathological pathway resulting from tungsten exposure may involve oxidative stress.
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Introduction
Tungsten (also known as wolfram, W) is a strong, flexible
transition metal, with a high melting point. These traits have led to
it becoming an indispensable part of a broad range of industrial
and commercial processes and devices that are key in modern
lifestyles [1]. Tungsten metal and its alloys occur in consumer
products such as electronics, light bulb filaments, cemented
tungsten carbide grinding wheels, carbide tipped tools and
armaments [1].
Low level human exposure to tungsten occurs from the
atmosphere, drinking water and diet. Entry into the air and water
occurs during tungsten ore processing, alloy fabrication, tungsten
carbide production and use, as well as during municipal waste
combustion [2]. Currently, human exposures from air, drinking
water, and food are thought to be very low. The concentration of
tungsten in ambient air is approximately ,10 ng/m3 [3].
However, occupational exposure may result in higher body
burdens.
Recent reports have suggested that tungsten should be
considered as an emerging chemical toxicant of concern, [2] as
its chemical stability in the environment has been questioned.
When soil pH falls, tungsten becomes increasingly soluble and can
leach into underlying aquifers [3]. With production of tungsten
steadily rising (72,000 tons produced last year compared to 40,000
tons in 2002 [4]), and use becoming more widespread, the
potential for tungsten to further contaminate the environment is
increasing. Tungsten is known to be capable of biological
interaction and disruption of biochemical pathways and therefore
the human health impact must be considered [5].
Current knowledge of the toxicology of tungsten is fragmentary
[6]. To date no significant human health effects have been
attributed solely to tungsten exposure, although in vitro and animal
studies point to tungsten toxicity leading to pulmonary inflamma-
tion [7] and the development of cancer [8]. Interestingly, a recent
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epidemiological study suggests that tungsten exposure may be
linked to an increased risk of composite cardiovascular and
cerebrovascular disease (CCVD) [9]. There is also some evidence
of toxicity of ‘‘hard metal’’, which is an alloy or encapsulated
mixture, primarily composed of tungsten or tungsten carbide and
cobalt. Other tungsten alloys contain yttrium, thorium, copper,
nickel, iron, or molybdenum, thereby complicating toxicological
attribution. Pulmonary fibrosis, memory and sensory deficits, and
increased mortality due to lung cancer have been identified
following occupational exposure to dusts generated in the hard
metal industry [10]. Historically however, the respiratory and
neurological effects observed in workers using tungsten and cobalt
hard metal mixtures were thought to be caused by cobalt, not
tungsten [10].
Work by Agarwal et al. (2011) indicated that tungsten may
increase an individual’s risk of CCVD. In the current investiga-
tion, we have looked for further evidence of this association, and
specifically the association of tungsten exposure with stroke (a
cerebral vascular incident characterized by occlusion by an
embolus, thrombus, or cerebrovascular hemorrhage or vasospasm,
resulting in ischemia of the brain tissues normally perfused by the
damaged vessels). Stroke is currently the fourth leading cause of
death in the United States [11]. It has a complex multifactorial
etiology involving both genetic and environmental risk factors, of
which tungsten exposure may be one.
The National Health and Nutrition Examination Survey
(NHANES) constitutes a unique dataset with which to investigate
the health effects of tungsten. It contains urinary measures of
tungsten for 8614 participants aged between 18 and 74 years in six
cross sectional data sets spanning twelve years (1999–2009). For
the current investigation we have used data from all six waves to
investigate the human health effects of tungsten in adults.
Materials and Methods
Study Population
NHANES assesses the health and diet of the non-institutional-
ized US civilian population and is administered by the US
National Center for Health Statistics, Centers for Disease Control
and Prevention. The study protocol for NHANES was approved
by the National Centers for Health Statistics Institutional Review
Board and full details of NHANES survey design are available
elsewhere [12]. Respondents included in our analyses were those
aged 18 to 74 years (of those randomly selected by NHANES for
urinary heavy metal measurement) providing a focus on adult
health conditions. The 74 year age cut-off was selected to
minimize biases caused by non-representation of seniors in
institutions. Data were pooled from six independent cross-sectional
NHANES waves 1999–2000, 2001–2002, 2003–2004, 2005–
2006, 2007–2008 and 2009–2010 which provided a sample of
8,614 adults (18–74 years) for whom urinary tungsten values were
available.
Chemical Analyses
The US National Toxicology Program selected a range of
potentially harmful chemicals for human health for further study
in specimens from NHANES respondents. Heavy metals, includ-
ing tungsten were measured in the urine of a subsample of eligible
NHANES participants using inductively coupled plasma-mass
spectrometry (ICP-MS). This involves the dilution of urine samples
(1+9) with 2% (v/v), double-distilled, concentrated nitric acid
containing both iridium (Ir) and rhodium (Rh) for multi-internal
standardization as originally described by Mulligan et al [13]. The
same methodology of urinary heavy metal analysis has been
employed across all six NHANES waves utilized in this study. A
lower limit of tungsten detection was 0.018 ng/ml and within the
pooled data set 503 individuals had urinary tungsten concentra-
tions below the lower limit of detection. For analysis the urinary
tungsten concentration was first expressed as mg/mg of urinary
creatinine and subsequently log transformed.
Disease Outcomes
Disease outcomes were investigated in NHANES using a
questionnaire. Participants were asked ‘‘Has a doctor or other
health professional ever told you that you have…’’ for angina,
coronary heart disease, heart attack, stroke, asthma, diabetes,
emphysema, chronic bronchitis; arthritis, thyroid problems, any
kind of liver condition, or cancers. We concentrated particularly
on cardiovascular disease (CVD) and stroke, as tungsten has been
implicated previously in CCVD. We defined CVD as any reported
diagnosis of angina, heart attack or coronary heart disease. We
investigated stroke separately from CVD as each constitutes a
distinct global health issue. The self-reported diagnoses could not
be confirmed via medical records. However, the derived stroke
and CVD variables were associated with classical risk factors in
our NHANES demographic (Table S1). NHANES also has
information on the year of diagnosis for CVD and stroke. For
each NHANES wave we therefore calculated the number years
since diagnosis of CVD and stroke at the time of recruitment to
NHANES.
Statistical Analysis
Initially we calculated age and sex adjusted weighted means of
tungsten concentration for individuals with and without a stroke or
CVD diagnosis using a student t-test. We also investigated how the
concentration of tungsten varied as time since diagnosis increased.
Logistic regression models were then used to estimate odds ratios
(OR) and its 95% confidence interval (CI), to characterize a
potential association between tungsten exposure (continuous
variable) and either stroke or CVD (both binary outcomes). Both
crude and multivariable models were fitted, with the latter
adjusting for potential confounders (including age, sex, ethnicity,
socio-economic status (investigated using education and the
poverty income ratio), smoking status (adjusted for both packs
per year and serum cotinine), alcohol consumption, occupation,
clinical factors (BMI (classified as underweight, normal, over-
weight, obese and very obese), hypertension and hypercholester-
olemia), molybdenum and cobalt concentration.). For this
procedure we defined hypertension as either a systolic blood
pressure greater than 140 mm Hg, a diastolic pressure of greater
than 90 mm Hg or a self-reported prior diagnosis by a physician.
Hypercholesterolemia was defined as a blood cholesterol
.240 mg/dL or self-reported as a prior diagnosis by a physician.
We further adjusted our models for other diseases reported in
NHANES including cardiovascular disease or stroke (depending
on our outcome variable), diabetes and emphysema. We also
adjusted for a range of other heavy metals including (barium,
cadmium, lead, uranium and thallium).
Association between CVD or stroke and tungsten was
investigated using logistic regression, in the overall pooled data
using NHANES waves 1999–2009. To determine the reproduc-
ibility of our findings we also investigate the association between
urinary tungsten and stroke or CVD in each NHANES wave.
Each wave represents a separate cohort and therefore if
association is noted in more than one wave it increases the
validity of our findings.
In the pooled data we stratified our analyses by a) age to
investigate the association in the under 50 s (18–50 years) and b)
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Table 1. Demographics of the pooled dataset and the weighted mean urinary tungsten concentration for the various
demographic variables.
Pooled data Tungsten Concentration Significant variation in Tungsten
ng/ml (95% CI)
N 8614 0.14 (0.14–0.15)
Sex Male (%) 4223 (49.02) 0.16 (0.14–0.17) ,0.001 (0.278)
Female (%) 4391 (50.98) 0.13 (0.12–0.14)
Age (%) ,0.001 (0.0687)
18–24 years 1682 (19.53) 0.19 (0.16–0.22)
25–34 years 1530 (17.76) 0.17 (0.14–0.17)
35–44 years 1512 (17.55) 0.14 (0.12–0.15)
45–54 years 1427 (16.57) 0.14 (0.12–0.16)
55–64 years 1292 (15.00) 0.11 (0.10–0.12)
65–74 years 1171 (13.59) 0.12 (0.10–0.14)
Race/Ethnicity (%) ,0.001 (,0.001)
Mexican American 2054 (23.84) 0.17 (0.15–0.18)
Other Hispanic 408 (4.74) 0.11 (0.10–0.13)
Non-Hispanic White 3880 (45.04) 0.14 (0.13–0.15)
Non-Hispanic Black 1962 (22.78) 0.17 (0.15–0.18)
Other race 310 (3.60) 0.14 (0.12–0.16)
Level of Education 0.315 (0.555)
Less than high school diploma 2652 (30.82) 0.15 (0.14–0.17)
High school diploma 2178 (25.31) 0.14 (0.13–0.16)
Some college education 3775 (43.87) 0.14 (0.13–0.15)
Unknown 9 (0.10)
Annual Income 0.343 (0.510)
,$20,000 1230 (14.28) 0.16 (0.13–0.18)
$20,000 to $35,000 1121 (13.01) 0.14 (0.12–0.16)
$35,000 to $75,000 1719 (19.96) 0.13 (0.11–0.15)
.$75,000 1099 (12.76) 0.13 (0.11–0.15)
Unknown 3445 (39.99) 0.16 (0.14–0.17)
Body mass index (BMI) 0.0146 (0.002)
Low weight, BMI,18.5 169 (1.96) 0.18 (0.12–0.23)
Recommended, BMI 18.5–24.9 2566 (29.79) 0.15 (0.14–0.17)
Overweight, BMI 25.0–29.9 2872 (33.34) 0.14 (0.12–0.15)
Obese I, BMI 30.0–34.9 1586 (18.41) 0.13 (0.12–0.14)
Obese II, BMI.= 35.0 1289 (14.96) 0.15 (0.13–0.16)
Unknown 132 (1.53) 0.13 (0.08–0.17)
Smoking Status (pack year) 0.411 (0.643)
Never 1971 (22.88) 0.12 (0.11–0.14)
,20 years 938 (10.89) 0.14 (0.11–0.16)
20 to 39 years 497 (5.77) 0.12 (0.10–0.13)
.= 40 years 153 (1.68) 0.11 (0.10–0.15)
Unknown 5055 (58.68) 0.16 (0.15–0.17)
Survey Year ,0.001 (0.001)
1999–2000 1336 (15.51) 0.14 (0.13–0.16)
2001–2002 1533 (17.80) 0.13 (0.11–0.16)
2003–2004 1496 (17.37) 0.12 (0.10–0.13)
2005–2006 1390 (16.14) 0.16 (0.14–0.17)
2007–2008 1193 (13.85) 0.16 (0.14–0.17)
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sex. We also performed a sensitivity analysis to investigate the
associations when the 503 individuals with urinary tungsten
measures below the lower detection limit included.
As a sensitivity analysis we adjusted for urinary creatinine levels
in our models to allow for dilution effects, and for other variables
in the model (e.g., age, sex, race/ethnicity) to be independent of
effects of urinary creatinine concentration [14].
All analyses were weighted for the complex cluster sample
design and conducted using STATA/IC Version 12.1 (College
Station, US). Sampling errors were estimated using the Taylor Series
Linearization method to account for stratification and clustering.
Results
From 1999–2010 there is variation in the urinary tungsten
concentration with post 2003/4 waves having higher urinary
tungsten levels than other years (Table 1). Urinary tungsten
concentrations were altered significantly by race (higher in Non-
Hispanic Blacks and Hispanic Mexicans), BMI (highest in those
with low BMI) and socioeconomic status (higher in low income,
poorer educated individuals). Urinary tungsten concentration was
higher in the 203 individuals reporting a stroke diagnosis (0.25
versus 0.13 ng/ml P=0.06; Figure 1). As time since diagnosis
increased, the urinary tungsten concentration decreased (P,0.05;
Figure 1).
Our data provided evidence of increased odds of reporting
stroke as urinary tungsten concentration in adults (18–74 years)
increased (Table 2). Urinary tungsten was associated with stroke in
unadjusted (OR: 1.53, 95% CI: 1.14, 2.05) and adjusted models
(OR: 1.66, 95% CI: 1.17, 2.34). The inclusion of all urinary
tungsten measures did not alter our findings (OR: 1.51, 95% CI:
1.14, 2.00; Table 2). The odds of stroke was not altered when
other heavy metals were included in the model (OR: 2.10 (95%
CI: 1.24, 3.57)). Stratification by sex in the models demonstrated
that tungsten increased an individual’s odds of a stroke in females
and significance was approached in males (Male OR: 1.51, 95%
CI: 0.92, 2.46; Female OR: 2.07, 95% CI: 1.20, 3.60; Table 2).
Stratification by age, revealed that strong associations remained
between stroke and urinary tungsten in the under fifties (Table 2;
Adjusted OR 2.17, 1.33, 3.53) and these associations remained
when other diseases were considered in the model (OR: 4.13 (2.07,
8.24)).
Our findings were not altered when we adjusted for creatinine
in the model as supposed to adjusting the urinary tungsten
concentration (Table S2).
When we investigated the individual NHANES waves associ-
ations were evident between stroke and tungsten in four of the six
waves (2001–2002, 2005–2006, 2007–2008 and 2009–2010) in
crude models and two of the six (2007–2008 and 2009–2010) in
adjusted models (Table S3).
The evidence for association between tungsten and CVD was
considerably weaker. Tungsten concentrations were similar in
individuals reporting a diagnosis of CVD and individuals without
the condition (Figure 1). In the pooled data an association between
tungsten and CVD was noted in crude models but not in adjusted
models (Table 3). In the individual NHANES waves no association
was noted between urinary tungsten and CVD (Table S3).
Discussion
This study revealed a strong association between urinary
tungsten concentrations and stroke. The association between
higher tungsten concentrations, which reflect higher environmen-
tal and dietary exposures to tungsten, and stroke were consistent
and independent of traditional risk factors.
To date, few studies have considered the adverse human health
impacts of tungsten or the demographic variables that increase an
individual’s risk of elevated tungsten exposure. Using the
Table 1. Cont.
Pooled data Tungsten Concentration Significant variation in Tungsten
ng/ml (95% CI)
2009–2010 1666 (19.34) 0.15 (0.13–0.17)
P values represent statistical significance of the different tungsten concentrations for each demographic variable. The P value presented in () includes an adjustment for
urinary creatinine. Statistical comparisons excluded individuals in the unknown categoriesTables.
doi:10.1371/journal.pone.0077546.t001
Figure 1. Bar charts representing the mean urinary tungsten
concentrations in individuals with and without a self-reported
stroke or CVD diagnosis. Error bars represent the 95% confidence
intervals and the P value represents the comparison of tungsten
concentrations in people with and without a stroke diagnosis.
doi:10.1371/journal.pone.0077546.g001
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NHANES dataset we have demonstrated that urinary tungsten
concentration varied with both race and BMI. Individuals
reporting a stroke diagnosis were noted to have higher levels of
urinary tungsten and this appeared to be higher in individuals
whose stroke had occurred within the last decade.
Stroke
Our findings are consistent with an earlier study in which a
statistically significant relationship was noted between urinary
tungsten and CCVD in NHANES [9]. Our research builds on this
earlier work by examining the role of tungsten in both CVD and
stroke separately and in a much larger sample. The association
between tungsten and stroke was strong, with no attenuation of the
OR after adjustment for classical stroke risk factors. The
relationship remained when other co-morbidities (CVD, diabetes
and emphysema) were included in the model, suggesting that
tungsten may be involved in the etiology of stroke in some
individuals.
Stratification by age revealed that the association was also
evident in individuals less than fifty years old. Stroke predominates
in the elderly (those over 65 years of age) while stroke in younger
individuals is believed to involve genetic risk factors and have a
different etiology (with cardiac embolism predominating over
atherosclerosis) [15]. This may indicate that tungsten increases an
individual’s risk of stroke through pathway(s) that increase the risk
of atherosclerosis and embolism, although it was not possible to
investigate the different subtypes of stroke within the NHANES
data.
Stratification by gender suggested that tungsten increased the
odds of stroke in both males and females, but the OR was higher
in females. Whilst men are more likely to have a stroke, more
women actually die from strokes [16]. The reason behind this
disparity is unknown and cannot be fully explored in this cross
sectional study. In this study we had an even distribution of strokes
in males and females perhaps suggesting some bias in our data.
Previous studies have indicated that metal toxicity is involved in
stroke etiology [17]. The OR for stroke was not attenuated
following adjustment for cobalt (often considered to be the
principle toxic agent) and molybdenum. Other metals not
measured in NHANES, which can be alloyed with tungsten (e.g.
yttrium, thorium, copper, nickel) may contribute to the metal
toxicity observed and need to be considered further in future
Table 2. Odds Ratios and 95% confidence intervals representing the odds of a stroke diagnosis per 1 unit increase in log
transformed urinary tungsten (expressed as mg per mg of urinary creatinine) for NHANES participants less than 75 years of age or
less than 50 years of age.
Age Range in NHANES Included
18–74 years 18–49 years
Model Stroke Cases (Controls) Odds ratio Stroke Cases (Controls) Odds ratio
Crude 203 (7,902) 1.53 (1.14–2.05)** 46 (4,801) 1.53 (1.07–2.17)*
Adjusteda 64 (3,799) 1.66 (1.17–2.34)** 25 (2,481) 2.17 (1.33–3.53)**
Adjustedb 69 (4,084) 1.51 (1.14–2.00)** 28 (2,634) 1.75 (1.26–2.45)**
Males only 35 (2,079) 1.51 (0.92–2.46)? 11 (1,304) Insufficient cases
Females only 29 (1,720) 2.07 (1.20–3.60)* 14 (1,177) Insufficient cases
aThe adjusted models include age, sex, ethnicity, SES, smoking, occupation, BMI, hypertenstion, hypercholesterolemia, molybdenum and cobalt concentration as
covariates.
bIn this model all urinary tungsten measures were included, including the 503 individuals with a concentration below the lowest detectable limit.
Statistical significance is denoted by ?, * and ** representing P,0.1, P,0.05 and P,0.01 respectively.
doi:10.1371/journal.pone.0077546.t002
Table 3. Odds Ratios and 95% confidence intervals representing the odds of a CVD diagnosis per 1 unit increase in log
transformed urinary tungsten (expressed as mg per mg of urinary creatinine) for NHANES participants less than 75 years of age or
less than 50 years of age.
Age Range in NHANES Included
18–74 years 18–50 years
Model CVD Cases (Controls) Odds ratio CVD Cases (Controls) Odds ratio
Crude 445 (7,648) 1.17 (1.02–1.34)* 63 (4,779) 0.94 (0.67–1.31)
Adjusteda 145 (3,711) 1.11 (0.86–1.43) 28 (2,474) 0.92 (0.56–1.52)
Adjustedb 157 (3,989) 1.16 (0.93–1.47) 31 (2,627) 0.99 (0.64–1.55)
Males only 114 (2,121) 1.09 (0.80–1.49) 16 (1,297) Insufficient cases
Females only 43 (1,868) 1.16 (0.76–1.77) 12 (1,177) Insufficient cases
aThe adjusted models include age, sex, ethnicity, SES, smoking, alcohol consumption, occupation, BMI, hypertenstion, hypercholesterolemia, molybdenum and cobalt
concentration as covariates.
bIn this model all urinary tungsten measures were included, including the 503 individuals with a concentration below the lowest detectable limit.
Statistical significance is denoted by * representing P,0.05.
doi:10.1371/journal.pone.0077546.t003
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investigations. Whilst we cannot rule out their involvement, our
findings point to tungsten as being of critical importance in stroke
etiology of many of the cases considered here. If not, then tungsten
is apparently strongly correlated with some unidentified agent,
which itself underpins the development of stroke. Despite the
limited power of statistical analysis mentioned earlier tungsten was
still associated with stroke in multiple individual NHANES waves.
Each wave is a separate cross-sectional cohort and therefore
observing the association in more than one wave strengthens the
validity of our findings.
We anticipate that tungsten will interfere with biochemical
pathways as it can replace molybdenum (Mo) at metal binding
sites in proteins [18]. Mo occurs in a wide range of metalloen-
zymes and in eukaryotes, the most prominent Mo-enzymes are
nitrate reductase, sulfite oxidase, xanthine dehydrogenase, alde-
hyde oxidase, and the mitochondrial amidoximereductase [19]. If
tungsten were to replace Mo at the binding site of these proteins,
rendering them non- or partially functional, it is biologically
plausible that it could increase the risk of disease. For example, the
nitrate to nitrite ratio (which is controlled by nitrate oxidase) has
been implicated in stroke [20] and is known to be associated with
oxidative cellular damage via the production of reactive oxygen
species (ROS).
Furthermore tungsten and it’s alloys generate ROS [21] and
deplete glutathione in tissues [22], both of which are implicated in
stroke [23,24]. ROS can influence numerous cellular and vascular
pathways which are implicated in stroke pathophysiology.
Cardiovascular Disease
Logistic regression models revealed crude associations between
tungsten and CVD, but these were attenuated following adjust-
ment for potential confounders. This suggests that tungsten is not
involved in the CVD etiology.
Limitations
The trends observed could arise due to confounding factors we
did not recognize or measured. We did investigate associations in
individual waves of NHANES, demonstrating that stroke was
associated with urinary tungsten concentration in two waves. The
power of this analysis was limited by low numbers of stroke cases
reported in this study. Due to the cross-sectional nature of
NHANES, we do not have access to data on tungsten levels prior
to the development of a specific medical condition. Only single
measurements of heavy metal levels were determined, which may
not represent chronic exposure. However, urinary heavy metal
levels are usually considered as biomarkers of choice when
assessing chronic exposure. This study may also be subject to
survival bias wherein participants with the diseases of interest or
severe risk factors may be less likely to, or unable to participate in
the study. In the case of mortality from stroke in young people this
would only increase the strength of the association. The exclusion
of institutionalized individuals tends to exclude those with severe
illnesses following heavy metal exposure. However, this bias is
likely to result in an underestimation of the strength of associations
between tungsten and stroke.
Conclusions
Statistically significant correlations were observed between
stroke and urinary tungsten level. Independent replication in a
prospective cohort is now needed to confirm the associations
reported. If the associations reported here are confirmed in
independent studies, it should give impetus to work to identify the
mechanisms of action linking long-term, low-dose tungsten
exposure to adverse outcomes in humans. Given the substantial
negative effects on adult health that may be associated with
elevated tungsten and also given the potential for reducing human
exposure, our findings merit further research into the human
health effects of this metal.
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